Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2008;336:298 (9 February), doi:10.1136/bmj.39482.466019.DB
Owen Dyer
1 London
| The first 150 words of the full text of this article appear below. |
European laboratories have detected an unusually high rate of resistance to the antiviral drug oseltamivir (Tamiflu) in random samples of seasonal influenza virus taken from around the continent.
The European Centre for Disease Prevention and Control and other agencies reported last week that oseltamivir resistance had been detected in 59 of 437 influenza A (H1N1) isolates from around Europe, a rate of 14%. In previous years, resistance has generally been found in about 1% of isolates.
The highest rate of resistance was found in samples from Norway, with 12 out of 16 tested isolates resistant to oseltamivir. Austria and Italy reported no resistant strains, whereas in Germany, the Netherlands and Sweden, the rate of resistance was less than 10%. Resistance was found in 17% of French samples tested.
In Britain, the Health Protection Agency has reported finding oseltamivir resistance in eight of 162 isolates tested.
Although resistance to oseltamivir has
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
What can you learn from this BMJ paper? Read Leanne Tite's Paper+